WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
TrialSpark | December 21, 2020
TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients.
Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...
Publicist360 | April 09, 2020
Cytogenetics is a branch of biology, which correlates cytology and genetics. The correlation is used to study chromosomes and genes in cells and tissues. The study is conducted in relation to hereditary and variations in genes and number of chromosomes, which are used for the detection of genetic disorders as well as selection of precise therapies for treatment of these genetic disorders. Cytogenetics includes various techniques such as comparative genomic hybridization, fluorescence in situ hyb...
Bio-Techne Corporation | April 13, 2022
Bio-Techne Corporation launched 3G assay for automated process impurity assessment on the EllaTM immunoassay platform ( NASDAQ: TECH ) and Cygnus Technologies, a division of Maravai LifeSciences ( NASDAQ: MRVI ).
In cell and gene therapy applications, the purification of viral particles to reduce host cell protein (HCP) contamination is an important part of the viral production workflow. To guarantee HCP impurity clearance is performed in compliance with regulatory criteria, accurate quan...
Cedilla Therapeutics | November 17, 2021
Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the cli...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE